Boston Scientific approves new compensation plans and selects independent director
On November 17, 2026, the Boston Scientific board of directors approved the 2027 annual bonus plan and two long-term stock incentive programs for management. Simultaneously, the company announced that David S. Wichmann will become lead independent director effective January 1, 2027.
Key points
- The board approved the 2027 annual bonus plan and two stock-based programs running through 2029.
- The company retains the right to modify or suspend plans.
Compensation plan approvals and personnel changes
The board approved the 2027 annual bonus plan and two stock-based programs running through 2029. Additionally, David S. Wichmann will succeed Edward J. Ludwig as lead independent director, with Ludwig remaining on the board.
Annual bonus payouts depend on global sales, earnings per share, and quality goals. Long-term stock awards depend on total shareholder return compared to the S&P 500 Healthcare Index or sales growth against the financial plan.
Clawback policies and limitations
The company retains the right to modify or suspend plans. Compensation is subject to clawback policies, allowing the recovery of bonuses in cases of misconduct or material harm to the company. Upon termination of employment, stock award conditions change or result in forfeiture.
Original sources
- 8-K filing, November 17, 2026
- 8-K EX-10.2 filing, November 17, 2026
- 8-K EX-10.3 filing, November 17, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Boston Scientific
A notification in your browser or on your phone when we publish about Boston Scientific. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
